Notwithstanding these limitations, the major strengths of the study are the multicentre nature that allows for the generalisability of the results and the simultaneous characterisation of the super-responder phenomenon with anti-IL-5 therapies for eosinophilic disease that may drive clinicians in choosing between targeting therapies in patients with SEA and EGPA. This evidence concerns the gene IL5 and eosinophilic granulomatosis with polyangiitis.